José Estabil is currently Chief Business Officer at Cipherome, a venture-backed AI/genomics company personalizing medicine to limit adverse drug reactions. José developed projects in Tokyo, Seoul and Moscow, directed MIT’s international innovation activities, and found an entrepreneurial outlet at MIT by advising the launch, scale, and exit of Arctic Sand (acq: Murata), an MIT spin-out. Before moving to Boston, José develop three award winning semiconductor diagnostics products (KLA) and ran $100M+ semiconductor businesses in Silicon Valley. He started his career at IBM labs.
Philip Empey, UPitt
Mary V. Relling, St. Jude Children’s Research Hospital
Stuart Scott, Stanford
Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.